LAVA Therapeutics Announced Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
- LAVA Therapeutics N.V. (Nasdaq: LVTX) today announced initial clinical data from its ongoing Phase 1/2a study of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer (mCRPC).
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
HC Wainwright & Co. Initiates Coverage On LAVA Therapeutics with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Arthur He initiates coverage on LAVA Therapeutics (NASDAQ:LVTX) with a Buy rating and announces Price Target of $9.
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.
Nasdaq Turns Lower; Crude Oil Drops Sharply
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite turning negative on Monday.
Dow Drops Over 100 Points; Crude Oil Rises Over 1%
U.S. stocks traded mixed midway through trading, with the Dow Jones dropping more than 100 points on Monday.
US Stocks Mostly Higher; Nasdaq Rises Over 100 Points
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.